NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
IPO Year: 2017
Exchange: NASDAQ
Website: nucana.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | Outperform → Mkt Perform | William Blair | |
| 3/3/2022 | Outperform → Market Perform | Cowen & Co. | |
| 11/24/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and
William Blair downgraded NuCana from Outperform to Mkt Perform
Cowen & Co. downgraded NuCana from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously
424B5 - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
F-3 - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738's composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month. Hugh S. Griffith, NuCana's Founder and Ch
BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this cohort of 12 patients, most of whom had received at least two prior lines of PD-1 inhibitor therapy, nine (75%) achieved disease control, including two patients who achieved Partial Responses. One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achie
NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303 Studies Continue Unchanged with Encouraging Data on NUC-7738 plus Pembrolizumab to be Presented at the ESMO Annual Conference in September EDINBURGH, United Kingdom, Aug. 29, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan a
Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £7.0 million for the quarter ended June 30, 2024, as compared to a net loss of £5.4 millio
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 12:30 PM EDTLocation: New York, NY The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen's 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024Time: 8:30 AM EDTLocation: Virtual The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with c
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of March 31, 2024, NuCana had cash and cash equivalents of £12.9 million compared to £
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), ("NuCana" or the "Company"), announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") and the matter is closed. As announced on May 12, 2023, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depos
EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the Company's previously disclosed plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio") has been made effective. The ADS Ratio Change became effective on April 16, 2024 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty-five reverse ADS split and will have no impact on an ADS holder's proportional equity interest in the Company. The change in the A
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the Regulation of Genes Critical for Cancer Growth and Survival SAN DIEGO, April 09, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting. Title: Exposing the Heterogeneity of the Lipidome in the TME of Cutaneous Melanoma Following Treatment with NUC-7738 in Combination with anti-PD-1 Therapy Presentation date and time: April 9, 2024 from 1:30pm-5:00pm PDTAbstract number: 6222 The tumor microenvironment (TME) is a complex interpla
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13D/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13D/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)
Oppenheimer analyst Leland Gershell reiterates NuCana (NASDAQ:NCNA) with a Outperform and maintains $150 price target.
Oppenheimer analyst Leland Gershell maintains NuCana (NASDAQ:NCNA) with a Outperform, adjusts target to $150 from $4 (1-25 Reverse Stock Split)
NuCana (NASDAQ:NCNA) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.
NuCana plc (NASDAQ:NCNA), ("NuCana" or the "Company"), announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") and the matter is closed. As announced on May 12, 2023, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depositary Shares (the "ADSs") had been below $1.00 for 30 consecuti
NuCana plc (NASDAQ:NCNA) announced that the Company's previously disclosed plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio") has been made effective. The ADS Ratio Change became effective on April 16, 2024 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty-five reverse ADS split and will have no impact on an ADS holder's proportional equity interest in the Company. The change in the ADS Ratio is intended to further support the liquidity in the Comp
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
Oppenheimer analyst Leland Gershell reiterates NuCana (NASDAQ:NCNA) with a Outperform and maintains $4 price target.
Gainers Avalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 205.16% to $1.95. The market value of their outstanding shares is at $53.6 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 78.11% to $1.53. The market value of their outstanding shares is at $6.5 million. Akanda (NASDAQ:AKAN) shares moved upwards by 50.45% to $0.25. The company's market cap stands at $2.1 million. iBio (AMEX:IBIO) shares moved upwards by 27.98% to $4.3. The market value of their outstanding shares is at $14.9 million. Mesobl